| Current Price | $4.03 | Mkt Cap | $198.5M |
|---|---|---|---|
| Open | $4.16 | P/E Ratio | 7.25 |
| Prev. Close | $4.03 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $4.02 - $4.21 | Volume | 709,467 |
| 52-Wk Range | $1.86 - $4.44 | Avg. Daily Vol. | 1,139,020 |
A specialty pharmaceutical company focused on the development and commercialization of differentiated products that address growing markets and are based on proprietary oral drug delivery technologies.
| Current Price | $4.03 | Mkt Cap | $198.5M |
|---|---|---|---|
| Open | $4.16 | P/E Ratio | 7.25 |
| Prev. Close | $4.03 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $4.02 - $4.21 | Volume | 709,467 |
| 52-Wk Range | $1.86 - $4.44 | Avg. Daily Vol. | 1,139,020 |
The best Bull and Bear pitches based on recency and number of recommendations.
Turn around and highly profitable.
"Cancer risk" can't see this being a good investment for the next few months at least.http://www.forbes.com/2010/02/18/xenoport-glaxosmithkline-depomed-markets-equities-pharmaceuticals.html?partner=yahootix
Read the most recent pitches from players about ASRT.
Recs
XMFFlygal
(95.08)
Submitted: 12/14/2022 11:59:10 PM :
Start Price:
$3.82
NASDAQ:ASRT Score:
+1.32
Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2022 full-year net product sales to greater than $152 million, increased from its prior outlook calling for net product sales of greater than $141 million for the full year. The Company noted that net product sales to date in the fourth quarter have significantly exceeded its prior expectations used in formulating the Company’s outlook provided with its third quarter results on November 8, 2022.
7 PE
Said Dan Peisert, President and Chief Executive Officer of Assertio, “Net product sales in 2022 have consistently exceeded expectations. The revised outlook is driven by better than anticipated volume across the majority of our portfolio, and particularly Indocin. Our recent addition of Sympazan is also generating higher sales than our original projections.”
Recs
VladimirPoutine
(< 20)
Submitted: 2/6/2022 2:43:28 PM :
Start Price:
$2.39
NASDAQ:ASRT Score:
+77.24
Turn around and highly profitable.
Recs
NorthSeaAscend
(99.69)
Submitted: 7/24/2018 11:30:16 PM :
Start Price:
$8.18
NASDAQ:ASRT Score:
-96.75
volatile.
Find the members with the highest scoring picks in ASRT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Stormwind | 93.11 | 4/13/2020 |
|
5Y | $0.79 | +408.84% | +48.10% | +360.73 | 0 Comment | |
| drugtrader | 65.37 | 4/21/2020 |
|
5Y | $0.83 | +386.19% | +49.71% | +336.48 | 0 Comment | |
| ZeroDotCom | 22.77 | 10/9/2009 |
|
5Y | $5.80 | -30.52% | +285.20% | +315.72 | 0 Comment | |
| anticitradeshort | 26.79 | 4/20/2009 |
|
NS | $2.14 | +88.32% | +385.22% | +296.90 | 0 Comment | |
| BuyTheDip | 22.15 | 10/13/2009 |
|
5Y | $3.90 | +3.33% | +282.51% | +279.18 | 0 Comment | |
| joebowler210 | 88.33 | 10/14/2009 |
|
3M | $3.73 | +8.04% | +277.83% | +269.79 | 0 Comment | |
| WorldOnFire | 27.02 | 2/2/2011 |
|
3W | $8.31 | -51.50% | +215.02% | +266.52 | 0 Comment | |
| reed127 | < 20 | 6/14/2012 |
|
1Y | $4.99 | -19.24% | +210.40% | +229.64 | 0 Comment | |
| PDTBiotech | 50.99 | 9/28/2012 |
|
NS | $5.86 | -31.23% | +186.10% | +217.33 | 0 Comment | |
| Brxcqqq | 23.66 | 6/14/2007 |
|
1Y | $5.11 | -21.14% | +184.75% | +205.89 | 3 Comments |
See what the Wall Street professionals think, according to their public statements and filings.
